Walleye Capital’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
Other funds holding CCCC
Walleye Capital's CCCC Position: Q3 2026 in Review
Walleye Capital increased its C4 Therapeutics (CCCC) stake by 191% in Q3 2026, buying an estimated $821K and bringing the position to 335,310 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3363.
Walleye Capital first reported a position in CCCC in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.63M in Q4 2021. 91 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.
- Walleye Capital held 335,310 shares of C4 Therapeutics worth $1.12M as of Q3 2026.
- Walleye Capital bought 220,185 C4 Therapeutics shares in Q3 2026, an estimated $821K.
- C4 Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3363 holding.
- Walleye Capital first reported a position in C4 Therapeutics in Q4 2021 and has held it in 12 quarters since.
- Walleye Capital's C4 Therapeutics position peaked at $2.63M in Q4 2021.
- 91 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.